AU657751B2 - Modified complement system regulator - Google Patents

Modified complement system regulator Download PDF

Info

Publication number
AU657751B2
AU657751B2 AU15902/92A AU1590292A AU657751B2 AU 657751 B2 AU657751 B2 AU 657751B2 AU 15902/92 A AU15902/92 A AU 15902/92A AU 1590292 A AU1590292 A AU 1590292A AU 657751 B2 AU657751 B2 AU 657751B2
Authority
AU
Australia
Prior art keywords
protein
amino acid
analog
binding
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU15902/92A
Other languages
English (en)
Other versions
AU1590292A (en
Inventor
John P. Atkinson
Dennis Hourcade
Malgorzata Krych
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
Original Assignee
University of Washington
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Washington University in St Louis WUSTL filed Critical University of Washington
Publication of AU1590292A publication Critical patent/AU1590292A/en
Application granted granted Critical
Publication of AU657751B2 publication Critical patent/AU657751B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Environmental Sciences (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU15902/92A 1991-05-03 1992-04-29 Modified complement system regulator Ceased AU657751B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69551491A 1991-05-03 1991-05-03
US695514 1991-05-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU78424/94A Division AU691525B2 (en) 1991-05-03 1994-09-23 Modified truncated complement system regulators

Publications (2)

Publication Number Publication Date
AU1590292A AU1590292A (en) 1992-11-05
AU657751B2 true AU657751B2 (en) 1995-03-23

Family

ID=24793320

Family Applications (1)

Application Number Title Priority Date Filing Date
AU15902/92A Ceased AU657751B2 (en) 1991-05-03 1992-04-29 Modified complement system regulator

Country Status (5)

Country Link
US (6) US6897290B1 (online.php)
EP (2) EP1413587A2 (online.php)
JP (1) JP2793431B2 (online.php)
AU (1) AU657751B2 (online.php)
CA (1) CA2067653C (online.php)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482404B1 (en) 1989-10-12 2002-11-19 David James White Transplantation of tissue comprising a DNA sequence encoding a homologous complement restriction factor
EP1413587A2 (en) 1991-05-03 2004-04-28 Washington University Modified complement system regulator
US5976540A (en) * 1993-05-17 1999-11-02 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
SG52383A1 (en) 1993-05-17 1998-09-28 T Cell Sciences Inc Compositions comprising complement related proteins and carbohydrates and methods for producing and using said compositions
US5856300A (en) * 1994-05-12 1999-01-05 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5679546A (en) * 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
CA2171953C (en) * 1993-09-24 2003-02-04 John P. Atkinson Modified truncated complement system regulators
EP1493446A1 (en) * 1993-09-24 2005-01-05 Washington University Modified truncated complement system regulators
US5866402A (en) * 1995-05-05 1999-02-02 Chiron Corporation Chimeric MCP and DAF proteins with cell surface localizing domain
GB9604518D0 (en) * 1996-03-02 1996-05-01 Smithkline Beecham Plc Novel compounds
GB9624731D0 (en) * 1996-11-28 1997-01-15 Univ Leicester Complement inhibitor
GB9704519D0 (en) 1997-03-05 1997-04-23 Smithkline Beecham Plc Compounds
US6221621B1 (en) 1997-03-06 2001-04-24 Bard Diagnostic Sciences, Inc. Methods of screening for colorectal cancers in which a complement Factor I or related protein is associated
JP2001515589A (ja) * 1997-03-06 2001-09-18 バイオン ダイアグノスティック サイエンシーズ，インコーポレイテッド 補体レギュレーターまたはレセプタータンパク質を使用するスクリーニングおよび処置
WO2000061752A2 (en) * 1999-04-09 2000-10-19 Washington University Modified complement system regulators
EP1185283B1 (en) * 1999-05-25 2005-09-07 King Faisal Specialist Hospital And Research Centre Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
US20090054330A1 (en) * 1999-05-25 2009-02-26 Kotwal Girish J Novel Therapeutic Use of Viral Inflammation Modulatory Protein in Blocking Xenograft Rejection
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
CN1511041A (zh) * 2001-05-17 2004-07-07 ������ҩ�����޹�˾ 利用抑制cd21的药剂治疗抗体介导的病变的方法
CN100594037C (zh) 2002-11-15 2010-03-17 Musc研究发展基金会 通过补体受体2定向的补体调节剂
DE10343620A1 (de) * 2003-09-20 2005-04-28 Leibrock Maschinenfabrik Im Un Verfahren und Vorrichtung zum Erfassen der zum Rauen bestimmten Seitenbereiche von auf Leisten aufgebrachten Schuhschäften
US8124097B2 (en) * 2004-01-21 2012-02-28 Case Western Reserve University Hybrid and chimeric polypeptides that regulate activation of complement
DK1713503T3 (da) * 2004-02-10 2013-11-04 Univ Colorado Regents Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde
US7947267B2 (en) * 2004-10-08 2011-05-24 Potentia Pharmaceuticals, Inc. Viral complement control proteins for eye disorders
US8043609B2 (en) 2004-10-08 2011-10-25 Potentia Pharmaceuticals, Inc. Viral complement control proteins for eye disorders
US8911733B2 (en) * 2005-05-26 2014-12-16 Musc Foundation For Research Development Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
US20070004625A1 (en) * 2005-06-30 2007-01-04 Li Liang-Man Use of complement inhibitory proteins to treat spinal cord injury
EP1738763A1 (en) * 2005-06-30 2007-01-03 AVANT Immunotherapeutics, Inc. Use of complement inhibitory proteins to treat spinal cord injury
CA2625206C (en) 2005-10-08 2021-12-07 Potentia Pharmaceuticals, Inc. Compstatin and analogs thereof for eye disorders
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
PT2044111E (pt) 2006-06-21 2014-11-12 Univ Colorado Regents Abordagem seletiva do fator h do complemento para o tratamento de doenças
WO2008008986A2 (en) 2006-07-13 2008-01-17 University Of Iowa Research Foundation Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
CA2680344A1 (en) 2007-03-14 2008-11-20 Woodruff Emlen Humaneered anti-factor b antibody
US20110092446A1 (en) * 2007-07-20 2011-04-21 Cedric Francois Compositions and methods for treatment of trauma
WO2009121065A2 (en) * 2008-03-28 2009-10-01 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
RS20120461A1 (sr) 2009-07-02 2013-06-28 Musc Foundation For Research Development Metode za stimulaciju regeneracije jetre
EP2496259B1 (en) 2009-11-05 2017-02-22 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria
JP5986990B2 (ja) 2010-05-14 2016-09-06 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレート 改善された補体レセプター２（ｃｒ２）ターゲティング基
US9421240B2 (en) 2010-06-22 2016-08-23 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
MX2012014975A (es) 2010-06-22 2013-03-12 Univ Colorado Regents Anticuerpos al fragmento c3d de componente 3 de complemento.
WO2012031273A2 (en) 2010-09-03 2012-03-08 Stem Centrx, Inc. Novel modulators and methods of use
US20120148542A1 (en) 2010-12-10 2012-06-14 Lifeline Scientific, Inc. Machine perfusion with complement inhibitors
CA2835627C (en) 2011-05-11 2023-01-10 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
EP2723361B1 (en) 2011-06-22 2019-10-30 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
EP2557089A2 (en) * 2011-07-15 2013-02-13 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Compositions and methods for immunomodulation
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
EP3929206A1 (en) 2012-11-15 2021-12-29 Apellis Pharmaceuticals, Inc. Long-acting compstatin analogs and related compositions and methods
US10308687B2 (en) 2013-03-15 2019-06-04 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US20160168237A1 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
WO2017044811A1 (en) 2015-09-11 2017-03-16 Bruce Andrien Recombinant glycosylated eculizumab and eculizumab variants
CA3287719A1 (en) 2015-10-07 2026-03-02 Apellis Pharmaceuticals, Inc. Use of long-acting compstatin analog for treating a complement-mediated disorder
EP3359566A1 (en) 2015-10-07 2018-08-15 Alexion Pharmaceuticals, Inc. A method for treating age-related macular degeneration in a patient
KR102566634B1 (ko) 2016-06-28 2023-08-14 우니베르시테트 울름 보체 억제제 및 그의 용도
ES2888904T3 (es) 2016-10-19 2022-01-10 Alexion Pharma Inc Un método de cuantificación de C5a sin unir en una muestra
EP3529618B1 (en) 2016-10-19 2020-12-02 Alexion Pharmaceuticals, Inc. A method of quantitating unbound c5 in a sample
CN116059313A (zh) 2017-04-07 2023-05-05 阿佩利斯制药有限公司 给药方案以及相关组合物和方法
KR20240167712A (ko) 2017-12-15 2024-11-27 아펠리스 파마슈티컬스 인코포레이티드 투여 요법 및 관련 조성물 및 방법
WO2020232319A1 (en) 2019-05-15 2020-11-19 Insideoutbio, Inc. Modular therapeutics for the treatment of inflammatory diseases and cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6079790A (en) * 1989-07-21 1991-03-11 Washington University Recombinantly produced human membrane cofactor protein (mcp)
AU7865091A (en) * 1990-05-11 1991-12-10 Austin Research Institute, The Cd46 variants

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212071A (en) 1988-04-01 1993-05-18 The Johns Hopkins University Nucleic acids encoding a human C3b/C4b receptor (CR1)
US5109113A (en) * 1986-05-02 1992-04-28 Genentech, Inc. Membrane anchor fusion polypeptides
JPH0742235B2 (ja) * 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5256642A (en) * 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
IL89790A (en) 1988-04-01 2002-05-23 Johns Hopking University Nucleic acid sequences that encode and cells that produce cr1 protein and methods of production and purification
EP0537171B1 (en) * 1990-05-11 2002-09-18 The Austin Research Institute CD46 isoforms
EP1413587A2 (en) * 1991-05-03 2004-04-28 Washington University Modified complement system regulator
JPH05271288A (ja) 1992-02-21 1993-10-19 Mochida Pharmaceut Co Ltd 新規な薬理学的特性を有する蛋白質

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6079790A (en) * 1989-07-21 1991-03-11 Washington University Recombinantly produced human membrane cofactor protein (mcp)
AU7865091A (en) * 1990-05-11 1991-12-10 Austin Research Institute, The Cd46 variants

Also Published As

Publication number Publication date
CA2067653A1 (en) 1992-11-04
EP0512733A3 (online.php) 1994-08-03
US6521450B1 (en) 2003-02-18
JPH0616696A (ja) 1994-01-25
US6897290B1 (en) 2005-05-24
EP1413587A2 (en) 2004-04-28
CA2067653C (en) 2001-02-13
JP2793431B2 (ja) 1998-09-03
EP0512733A2 (en) 1992-11-11
AU1590292A (en) 1992-11-05
US5545619A (en) 1996-08-13
US6010873A (en) 2000-01-04
US5719127A (en) 1998-02-17
US20080119400A1 (en) 2008-05-22

Similar Documents

Publication Publication Date Title
CA2067653C (en) Modified complement system regulator
Martin et al. Determination of the structural basis for selective binding of Epstein-Barr virus to human complement receptor type 2.
AU705745B2 (en) Novel hIL-4 mutant proteins as antagonists or partial agonists of human interleukin 4
US5856126A (en) Peptide having anti-thrombus activity and method of producing the same
KR20010023325A (ko) 함지방세포-특이적 단백질 상동체
WO1992022320A1 (en) C1 inhibitor variants and treating inflammatory response with c1 inhibitor
US5663070A (en) Recombinant production of a soluble splice variant of the Fas (Apo-1) antigen, fas TM
IL154248A (en) Antibody against melanoma-inhibiting protein
EP0730469B1 (en) Modified truncated complement system regulators
CA2046925A1 (en) Pregnancy specific proteins applications
WO1996020957A1 (en) Anti-inflammatory cd14 polypeptides
Galat et al. Cyclophilin‐B is an abundant protein whose conformation is similar to cyclophilin‐A
HK1065552A (en) Modified complement system regulator
US5556945A (en) Tumor suppressor gene
US6747138B1 (en) Methods and compositions for regulating Fas-associated apoptosis
Tejada et al. Cloning of an avian antithrombin: developmental and hormonal regulation of expression
WO2000061752A2 (en) Modified complement system regulators
US20020142372A1 (en) Fragments of cr1 and their use
EP0627486A1 (en) New extracellular superoxide dismutase, a process for preparing the same and compositions containing the same
EP1493446A1 (en) Modified truncated complement system regulators
US5756333A (en) Recombinant production of lactoperoxidase
Colin et al. Gerbich Blood Groups and Minor Glycophorins
WO1995004756A1 (en) Complement inhibitor proteins of non-human primates
HK1072725A (en) Modified truncated complement system regulators
Schenkel-Brunner Gerbich System